NCT07014540View on ClinicalTrials.gov

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Neuroendocrine Carcinomas (NEC)
Interventions
DRUG

Irinotecan Hydrochloride Liposome Injection

Liposome irinotecan (70/50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week

DRUG

5-FU

5-FU (2400mg/m\^2) will be administered by continuous infusion for 46 hours in a 2-week

DRUG

LV

LV (400mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week

Trial Locations (1)

Unknown

Beijing GoBroad Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Beijing GoBroad Hospital

OTHER

NCT07014540 - A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | Biotech Hunter | Biotech Hunter